H2A.Z.2 deficiency sensitizes melanoma cells to chemotherapy and to MEK (also known as mitogen-activated protein kinase (MAPK) kinase or MAP2K) inhibitors, indicating it as an important mediator of cell proliferation and drug sensitivity in malignant melanoma (52). This evidence concerns the gene WNK2 and melanoma.